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Abstract
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple
myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73
hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were
compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted
at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were
male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was
moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required
by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive
ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients,
inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at
hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent
prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies
predictors of inpatient mortality among MM patients hospitalized with COVID-19.
Introduction
In December 2019, a cluster of patients with pneumonia
linked to a previously unknown coronavirus, now named
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was detected in Wuhan, China1. This rapidly
evolved into a pandemic of the heterogeneous clinical
disease named coronavirus disease 2019 (COVID-19) that
has challenged healthcare systems and led to thousands of
deaths worldwide. The clinical presentation is highly
variable, ranging from asymptomatic cases to severe
respiratory infections. It is associated with a pro-
inflammatory status, leading to cytokine release syn-
drome and hypercoagulation, with multi-organ damage
and fatal outcome2. It was soon recognized that various
factors, including increased age (>65 years, and particu-
larly >75 years), male sex, and presence of comorbidities
(cardiovascular comorbidity, obesity, hypertension, and
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diabetes) contributed substantially to the severity of
COVID-19. Investigations of novel strategies for the
prevention and treatment of COVID-19 (including anti-
malarials, antiviral drugs, antibiotics, anti-interleukin-6/-1
therapies, and anticoagulants), together with appropriate
intensive supportive care, have aimed to improve patient
outcome3,4. There are cumulative data indicating that
patients with cancer may be at increased risk for more
severe COVID-19 and associated complications, including
those receiving or not receiving treatment within the
month prior to infection5,6, although other recent results
suggest mortality may be primarily associated with age,
male sex, and comorbidities7.
Multiple myeloma (MM) is a malignant proliferation of
clonal B lymphoid cells at the last stage of maturation
(plasma cells) that are responsible for the secretion of
immunoglobulins (Igs). Impairment of Ig production,
with the coexistence of a monoclonal component (M-
component) plus immunosuppression of normal Igs, leads
to severely impaired humoral immunity. Additionally,
MM patients display dysfunctional cellular and innate
immunity; this complex failure of immunosurveillance
mechanisms makes MM patients highly susceptible to
viral and bacterial infections8. Some MM treatments may
also positively or negatively impact the immune system.
The most common side-effect of MM treatment is the
induction of cytopenia, which is clearly associated with
increased susceptibility to bacterial and viral infections.
Chemotherapy, particularly high-dose melphalan, results
in these side effects. Corticosteroids have well-established
immunosuppressive effects. Proteasome inhibitors induce
T-cell dysfunction and are associated with an increased
risk for varicella-zoster virus reactivation9. Immunomo-
dulatory drugs may have a protective effect by increasing
natural killer (NK) and T-cell function but are also
associated with cytopenia and an increased risk for venous
thromboembolism10. CD38 monoclonal antibodies
reduce NK and immunosuppressive regulatory T cells,
and are associated with higher incidences of viral and
bacterial infections8,11,12.
To date, there is very limited information regarding
characteristics and outcomes of MM patients with
COVID-19, with only a single case report13 and a small
UK series of 75 heterogeneous patients that did not report
a non-MM reference group of patients with COVID-1914.
Several international and national guidelines have been
reported15–19, providing guidance to physicians on the
management of patients with MM during the COVID-19
pandemic; however, these recommendations are based on
consensus and general disease concepts, and lack specific
data derived from infected patients. To our knowledge,
this is the first large case-series study to describe com-
prehensively the clinical characteristics of COVID-19 in
hospitalized MM patients, compare outcomes with a
noncancer cohort of COVID-19 patients, and identify
preadmission prognostic factors of inpatient mortality.
Methods
This multicenter case-series analysis was performed at a
national level by the Spanish Myeloma Collaborative
Group (Programa Español de Tratamientos en Hemato-
logía14,20/Grupo Español de Mieloma8). The study was
approved by the Institutional Review Board (IRB) of
Hospital Universitario 12 de Octubre (n 20/208). This
case-series study includes MM patients who were
admitted to a participating hospital with a SARS-CoV-2
polymerase chain reaction (PCR)-positive test between
March 1 and April 30, 2020. Additionally, a series of
patients with no cancer history, matched by age and sex,
were randomly selected from cohorts of COVID-19
patients admitted during the same time period at six
participating hospitals.
Clinical specimens were obtained by nasopharyngeal
swab collection in accordance with Spanish disease con-
trol and prevention guidelines. Samples were processed at
local microbiology laboratories, and SARS-CoV-2 one-
step real-time reverse transcriptase (rRT)-PCR diagnostic
assay was performed.
A modified version of a questionnaire proposed by the
International Myeloma Society was used for data extrac-
tion. A common set of demographic, clinical, laboratory,
treatment, and outcome variables were collected for the
MM and noncancer cohorts of hospitalized COVID-19
patients. Specific disease status and treatment data were
obtained for MM patients. Data extraction was performed
locally by hematology departments in participating hos-
pitals and centrally processed by the PETHEMA/GEM
data-monitoring unit. Hospital outcome status was
defined as discharge from the hospital or receiving
ongoing care (survivor group) or death (non-survivor
group).
Statistical analysis
Demographic, clinical, laboratory, and therapy covari-
ates and hospital outcomes were summarized using
descriptive statistics. Continuous variables were reported
as the median and interquartile range (IQR). Generic
COVID-19 patient characteristics and specific MM fea-
tures were analyzed according to the two hospital out-
come categories. Crude and adjusted odd ratios (OR) with
95% confidence intervals (CI) were estimated with logistic
regression analysis for a predefined set of well-established
prognostic factors. Preadmission characteristics, MM
status, and comorbidities constituted the reference model
and were used to adjust the association of relevant MM
features with mortality. To limit model overfitting, the
number of events per candidate variable was restricted to
>10. Calibration and discrimination of the resulting
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models were assessed using the Hosmer–Lemeshow
goodness-of-fit test and the c-statistic21. We assessed
internal validity with a bootstrapping procedure that used
500 replicate samples to gain insight into the stability of
the reference model22. Analyses were generated using
SAS/STAT software, Version 9.4, SAS Institute Inc.
Results
Between March 1 and April 30, 2020, 216 patients with
MM and SARS-Cov-2 infection detected by RT-PCR were
reported from 73 healthcare centers. Thirty patients were
excluded because of a diagnosis of a plasma cell disorder
other than MM; 19 patients were excluded because they
did not require hospital admission (Fig. 1). As of May 20,
2020, one patient remained hospitalized and receiving
ongoing care. The temporal and geographical distribution
of reported cases matched the distribution of the epi-
demic in Spain; 114 (68%) were confirmed in the first
3 weeks of the lockdown period (March 15 to April 4).
Eligible cases were notified from 29 of 50 provinces (58%),
with 108 (65%) reported from two provinces with high
population excess mortality.
The characteristics and clinical features of the 167 MM
patients and the 167 noncancer patients are described in
Table 1. Concerning COVID-19 clinical features, 77 and
89% of MM and noncancer patients, respectively, pre-
sented with moderate–severe disease, and 8 and 4% had a
critical disease. The proportion of patients requiring
supplemental oxygen was 47 and 55% in MM and non-
cancer patients, respectively. Numerically, more MM
patients required noninvasive and invasive ventilation
(21% and 9%, respectively) compared to the noncancer
group (8% and 6%, respectively). At hospital admission,
MM patients had numerically lower median levels of
neutrophils, lymphocytes, and platelets, and numerically
higher concentrations of D-dimers and ferritin compared
with noncancer patients (Table 1). Treatments adminis-
tered to the two groups of patients are summarized in
Table 1; 31% of MM patients received triple-combination
therapy including (hydroxy)chloroquine, azithromycin,
All reported cases in Spain 
n = 216 
From 62 centers in 15/17 (88%) 
regions and 32/50 (64%) provinces 
All reported cases in patients with 
multiple myeloma
n = 186
From 59 centers in 14/17 (82%) 




reporting multiple myeloma patients
with COVID-19 between 
March 1 and April 30, 2020 
n = 73
From 17/17 (100%) regions 
and 38/50 (76%) provinces in Spain
Centers excluded as reporting 0 
cases
n = 11 (15%)
Patients excluded, due to not 
having a diagnosis of multiple 
myeloma
n = 30 (14%)
• Amyloidosis (n = 10)
• Monoclonal gammopathy of 
undetermined significance 
(n = 10)




Patients excluded due to being 
PCR-negative for COVID-19
n = 0
All reported cases in patients with 





Patients excluded due to being 
treated as outpatients for 
COVID-19
n = 19 (10%)
All cases in hospitalized patients 
with multiple myeloma and 
PCR-positive for COVID-19
n = 167 (90%)
From 57 centers in 14/17 (82%) 
regions and 29/50 (58%) provinces 
Fig. 1 Flow chart of the patients included in the study. Flow diagram of patients with multiple myeloma admitted to hospital with COVID-19 who
were included in the present analysis.
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and retroviral compared with 42% of the noncancer
group. Regarding outcomes, inpatient mortality was 34%
in the MM group and 23% in the noncancer group.
MM- and COVID-19-related characteristics according to
hospital outcome
Preadmission characteristics of MM patients according
to hospital outcome are presented in Table 2; 56 patients
(34%) died during hospitalization (non-survivor group),
110 (66%) were discharged, and 1 patient remained hos-
pitalized receiving ongoing care (survivor group). Mor-
tality was 41% in males and 24% in females. Mortality was
Table 1 Preadmission features, COVID-19 clinical,
laboratory, and therapy features, and COVID-19 outcome
in multiple myeloma (MM) and noncancer patients









Age, median (IQR), years 71 (62–78) 71 (63–78)
Age groups
<65 years 55 (33) 55 (33)
65–74 years 55 (33) 55 (33)
≥75 years 57 (34) 57 (34)
Sex
Male 95 (57) 95 (57)
Female 72 (43) 72 (43)
Comorbidities
At least one 126 (75) 129 (77)
None 41 (25) 38 (23)
Cardiac disease 35 (21) 32 (19)
Pulmonary disease 23 (14) 34 (20)
Diabetes 28 (17) 36 (22)
Renal disease 32 (19) 13 (8)
Hypertension 67 (40) 79 (47)
COVID-19 clinical features
Clinical severitya
Mild 26 (15) 11 (7)
Moderate–severe 128 (77) 149 (89)
Critical 13 (8) 6 (4)
Respiratory supporta
No supplemental oxygen 39 (23) 51 (31)
Supplemental oxygen 78 (47) 91 (55)
Noninvasive ventilation 35 (21) 14 (8)




Absolute neutrophil count, ×109/
L
2.78 (1.7–4.7) 4.8 (3.54–6.3)
Lymphocyte count, ×109/L 0.515
(0.24–0.815)
0.99 (0.7–1.42)












Ferritin, ng/mL 995 (486–2070) 761 (401–1528)
COVID-19 therapy
(Hydroxy)chloroquine 148 (89) 157 (94)
Azithromycin 91 (54) 115 (69)
Antiretrovirals 103 (62) 103 (62)
Antiviral combination therapy
None 11 (7) 5 (3)
(Hydroxy)chloroquine only 16 (10) 14 (8)
(Hydroxy)chloroquine and
retroviral
47 (28) 31 (19)
(Hydroxy)chloroquine and
azithromycin
34 (20) 42 (25)
(Hydroxy)chloroquine,
azithromycin, and retroviral
51 (31) 70 (42)
Other combination 8 (5) 5 (3)
Steroids 83 (50) 62 (37)
Anti-interleukin-6 receptor
antibody therapy
22 (13) 27 (16)
Steroids and anti-interleukin-6
receptor antibody therapy
21 (13) 16 (10)
Heparin 109 (65) 117 (70)
COVID-19 outcome (hospital
outcome)
Receiving ongoing care 1 (<1) 2 (1)
Hospital discharge 110 (66) 127 (76)
Hospital death 56 (34) 38 (23)
COVID-19 coronavirus disease 2019, IQR interquartile range.
aData missing for one patient in the noncancer group.
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Table 2 Characteristics of multiple myeloma (MM)
patients with COVID-19, according to hospital outcome.
Patients with hospital outcome, N (%)






Age, median (IQR), years 71 (62–78) 70 (58–77) 75 (68–79)
Age groups, years, n (%) % shown as the proportion
of “all”
≤49 6 (4) 6 (100) 0
50–59 29 (17) 24 (83) 5 (17)
60–69 41 (24) 25 (61) 16 (39)
70–79 60 (36) 37 (62) 23 (38)
≥80 31 (19) 19 (61) 12 (39)
Sex
Males 95 (57) 56 (59) 39 (41)
Females 72 (43) 55 (76) 17 (24)
MM features % shown as the proportion
of “all”
Monoclonal component
Immunoglobulin G 83 (50) 61 (73) 22 (27)
Immunoglobulin A 42 (25) 25 (60) 17 (40)
Immunoglobulin D 2 (1) 2 (100) 0 (0)
Immunoglobulin M 3 (2) 2 (67) 1 (33)
Non-secretory disease 3 (2) 2 (67) 1 (33)
Light chain only disease 34 (21) 19 (56) 15 (44)
International staging system disease stageb
I 47 (28) 34 (72) 13 (28)
II 61 (37) 42 (69) 19 (31)
III 57 (35) 35 (61) 22 (39)
Cytogenetic classification by
FISHc
High risk 36 (24) 23 (64) 13 (36)
Other/standard risk 114 (76) 75 (66) 39 (34)
Bone disease at diagnosis of
MM
Yes 129 (77) 86 (67) 43 (33)
No 38 (23) 25 (66) 13 (34)
Renal disease at diagnosis
of MM
Yes 45 (27) 22 (49) 23 (51)
No 122 (73) 89 (73) 33 (27)
Table 2 continued
Patients with hospital outcome, N (%)






Year of diagnosis of MM
(time since diagnosis)
2020 (0–3 months) 25 (15) 13 (52) 12 (48)
2019 (4–18 months) 30 (18) 24 (80) 6 (20)
≤2018 (≥18 months) 112 (67) 74 (66) 38 (34)
Prior stem cell
transplantationd
Yes 51 (31) 42 (82) 9 (18)
No 113 (69) 67 (59) 46 (41)
Prior lines of treatment
for MMe
1 82 (51) 58 (71) 24 (29)
2 39 (24) 23 (59) 16 (41)
>3 41 (25) 27 (66) 14 (34)
Prior therapy class
Proteasome inhibitor 138 (83) 92 (67) 46 (33)
No proteasome inhibitor 29 (17) 19 (66) 10 (34)
Immunomodulatory drug 119 (71) 80 (67) 39 (33)
No
immunomodulatory drug
48 (29) 31 (65) 17 (35)
Monoclonal antibody 38 (23) 25 (66) 13 (34)
No monoclonal antibody 129 (77) 86 (67) 43 (33)
MM status and comorbidities at
hospital admission for COVID-19





43 (26) 22 (51) 21 (49)
Partial response 72 (43) 52 (72) 20 (28)
Complete response 52 (31) 37 (71) 15 (29)
Comorbidities
At least one 126 (75) 79 (63) 47 (37)
None 41 (25) 32 (78) 9 (22)
Cardiac disease 35 (21) 22 (63) 13 (37)
No cardiac disease 132 (79) 89 (67) 43 (33)
Pulmonary disease 23 (14) 14 (61) 9 (39)
No pulmonary disease 144 (86) 97 (67) 47 (33)
Diabetes 28 (17) 18 (64) 10 (36)
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16% in patients aged <65 years compared to 42% in those
aged >65 years, including 40% in patients aged 65–75
years and 44% in those aged >75 years. None of the female
patients aged <65 years died.
Concerning MM features, inpatient mortality was 27
and 28% in patients with an IgG M-component and stage
I disease at diagnosis, respectively. Cytogenetic abnorm-
alities and the presence of bone disease did not impact
inpatient mortality. However, in patients with renal
impairment at MM diagnosis inpatient mortality was 51%
vs 27% in patients with normal renal function. Prior
treatment with immunomodulatory drugs, proteasome
inhibitors, or monoclonal antibodies did not impact
inpatient mortality (Table 2).
With regards to the year of MM diagnosis, 12 of 25
patients (48%) diagnosed between January and April 2020
(during the emerging pandemic) did not survive COVID-
19. To understand this high mortality rate, we analyzed
the characteristics of the cohort. Of note, 10 (83%) of
the 12 non-survivors were male, 11 (92%) had a M-
component other than IgG, 9 (75%) had international
staging system stage III disease, 7 (58%) presented with
renal impairment, and 7 (58%) had active disease. By
contrast, 82% of patients who had received autologous
stem cell transplantation (ASCT) survived COVID-19,
while 41% of the non-ASCT group died (Table 2).
Regarding MM status and comorbidities at the time of
COVID-19 admission, in patients with active/progressive
disease, the inpatient mortality rate was 49% compared to
28 and 29% for patients in partial or complete response,
respectively (Table 2). Patients with at least one comor-
bidity had an inpatient mortality rate of 37% vs 22% in
those without comorbidities. The mortality rate was
numerically higher in MM patients with vs without car-
diac (37% vs 33%) or pulmonary (39% vs 33%) comor-
bidities or hypertension (42% vs 28%); the presence of
renal disease was associated with the numerically highest
mortality rate (59%). Immunoparesis did not affect the
mortality rate.
Table 3 summarizes clinical and laboratory features at
admission according to hospital outcome. Patients with
higher values (above the median) for the neutrophil count,
D-dimers, and ferritin had higher mortality rates (43%,
40%, and 32%, respectively) than those in patients with
lower values (below the median; 25%, 22%, and 22%,
respectively). The opposite effect was observed for lym-
phocyte and platelet counts, with lower values associated
with a higher mortality rate (40% vs 28 and 41% vs 25%,
respectively).
The association with inpatient mortality was estimated
for nine prognostic factors assessed before admission
(Table 4). In an unadjusted analysis, seven factors were
associated with increased odds of death: male sex, age >65
years, renal disease and hypertension as comorbidities,
diagnosis of MM in 2020, renal disease at diagnosis, and
active/progressive disease at the time of COVID-19 hos-
pitalization (Table 4). IgG M-component and prior ASCT
were associated with lower inpatient mortality. In an
adjusted analysis, male sex, age >65 years, active/pro-
gressive disease, and renal disease as comorbidity were
independent prognostic factors of inpatient mortality. The
combination of this set of independent factors constituted
a stable prognostic model of inpatient mortality; the
bootstrapping procedure corrected the discriminatory
ability of this reference model in terms of c-statistic from
0.79 to 0.765. No other candidate variable improved the
prognostic performance of the reference model in terms
of calibration and discrimination (Table 4).
Discussion
This study provides a comprehensive description of the
characteristics and outcomes of MM patients hospitalized
with confirmed SARS-CoV-2 infection in Spain. Mortality
was 50% higher in MM patients (34%) vs noncancer
patients (23%). The main predictors of inpatient mortality
for MM were male sex, age >65 years, renal disease, and
active/progressive disease.
This is a highly representative series for gaining insights
into the impact of COVID-19 in the MM population; all
Spanish hospitals were put under the governance of the
Ministry of Health, and the structure of PETHEMA/GEM
includes most centers treating MM patients within
Table 2 continued
Patients with hospital outcome, N (%)






No diabetes 139 (83) 93 (67) 46 (33)
Renal disease 32 (19) 13 (41) 19 (59)
No renal disease 135 (81) 9 (73) 37 (27)
Hypertension 67 (40) 39 (58) 28 (42)
No hypertension 100 (60) 71 (72) 28 (28)
Immunoparesisf 104 (69) 67 (65) 37 (31)
No immunoparesis 46 (31) 30 (65) 16 (35)
COVID-19 coronavirus disease 2019, FISH fluorescence in situ hybridization, IQR
interquartile range.
aIncludes one patient who remains hospitalized receiving ongoing care.
bData missing for two patients who died in the hospital.
cData missing for 17 patients, 13 who were discharged and 4 who died in the
hospital.
dData missing for three patients, two who were discharged and one who died in
the hospital.
eData missing for five patients, three who were discharged and two who died in
the hospital.
fData missing for 16 patients, 13 who were discharged and 3 who died in
hospital.
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Spanish territory. The selected time-frame corresponded
to peak COVID-19 incidence and population excess
mortality in Spain. Additionally, to gain a more precise
picture of the differential features of these patients, we
obtained clinical and laboratory characteristics and hos-
pital outcomes from a concomitant series of SARS-CoV-
2-infected noncancer patients. To assure uniformity, the
Table 3 Patient characteristics at hospital admission for
COVID-19, according to hospital outcome.









Clinical features during admission % shown as the proportion of
“all”
Clinical severity
Mild 26 (16) 24 (92) 2 (8)
Moderate–severe 128 (77) 85 (66) 43 (34)
Critical 13 (8) 2 (15) 11 (85)
Respiratory support
No supplemental oxygen 39 (23) 36 (92) 3 (8)
Supplemental oxygen 78 (47) 56 (72) 22 (28)
Noninvasive ventilation 35 (21) 13 (37) 22 (63)
Invasive ventilation 15 (9) 6 (40) 9 (60)
Laboratory measures at hospital
admission
% shown as the proportion of
“all”
Absolute neutrophil countb
Above median 80 (50) 46 (57) 34 (43)
Below median 79 (50) 59 (75) 20 (25)
Lymphocyte countc
Above median 79 (50) 57 (72) 22 (28)
Below median 78 (50) 47 (60) 31 (40)
Plateletsd
Above median 77 (51) 58 (75) 19 (25)
Below median 75 (49) 44 (59) 31 (41)
D-dimers
Above mediane 67 (51) 40 (60) 27 (40)
Below medianf 64 (49) 50 (78) 14 (22)
Ferriting
Above median 41 (50) 28 (68) 13 (32)
Below median 41 (50) 32 (78) 9 (22)
COVID-19 therapy % shown as the proportion of
“all”
(Hydroxy)chloroquine 148 (89) 101 (68) 47 (32)
No (hydroxy)chloroquine 19 (11) 10 (53) 9 (47)
Azithromycin 91 (54) 62 (68) 29 (32)
No azithromycin 76 (46) 49 (64) 27 (36)
Antiretrovirals 103 (62) 65 (63) 38 (37)
No antiretrovirals 64 (38) 46 (72) 18 (28)
Table 3 continued










None 11 (6) 6 (55) 5 (45)
(Hydroxy)chloroquine only 16 (10) 11 (69) 5 (31)
(Hydroxy)chloroquine and
retrovirals
47 (28) 30 (64) 17 (36)
(Hydroxy)chloroquine and
azithromycin
34 (20) 27 (79) 7 (21)
(Hydroxy)chloroquine,
azithromycin, and retrovirals
51 (31) 33 (65) 18 (35)
Other combination therapy 8 (5) 4 (50) 4 (50)
Steroids 83 (50) 51 (61) 32 (39)
No steroids 84 (50) 60 (71) 24 (29)
Anti-interleukin-6 receptor
antibody therapy
22 (13) 15 (68) 7 (32)
No anti-interleukin-6
receptor antibody therapy




21 (13) 14 (67) 7 (33)
No steroids and anti-
interleukin-6 receptor
antibody therapyf
143 (87) 95 (66) 48 (34)
Heparin 109 (65) 77 (71) 32 (29)
No heparin 58 (35) 34 (59) 24 (41)
COVID-19 coronavirus disease 2019, IQR interquartile range.
aIncludes one patient who remains hospitalized receiving ongoing care.
bData missing for eight patients, six who were discharged and two who died in
hospital.
cData missing for 11 patients, 8 who were discharged and 3 who died in
hospital.
dData missing for 16 patients, 10 who were discharged and 6 who died in
hospital.
eData missing for 36 patients, 21 who were discharged and 15 who died in the
hospital.
fData missing for 85 patients, 51 who were discharged and 34 who died in the
hospital.
gData missing for three patients, two who were discharged and one who died in
the hospital.
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study focused solely on patients requiring hospital
admission—we did not include MM patients who were
treated as outpatients for COVID-19 and either was PCR-
positive or just had COVID-19-compatible symptoma-
tology since, in such a population, obtaining a complete
case history could not be guaranteed.
Participating centers covered the whole geographical
territory of Spain, although half of the cases were reported
from the Madrid region, where a higher number of
COVID-19 cases were confirmed at the national level. A
large number of participating hospitals (n= 73) ensured a
representative mix of cases. The central data-monitoring
unit worked closely with local sites to confirm data and on
patient follow-up. Participating centers were long-term
contributors to the PETHEMA/GEM research program;
local data extractors at each site implemented common
data element definitions.
The selection of prognostic factors for estimating adjus-
ted associations with inpatient mortality rate was based on
clinical credibility and restricted in number to limit model
overfitting. The assessment of internal validity confirmed
the stability of the model, and that factor estimates were
realistic for similar future patients. We assessed the risk of
study bias with the QIPS tool for prognostic factors studies
and concluded that the reported results are unlikely to be
distorted, spurious, or biased23. The independent prog-
nostic factors that we identified were measurements
available prior to hospital admission. A prognostic model
including these factors could be developed to risk-stratify
MM patients and to implement preventive strategies in the
event of a healthcare crisis.
As noted, inpatient mortality was higher in MM vs
noncancer patients. This occurred despite the similarity
between groups in the clinical severity of COVID-19.
Rates of comorbidities appeared comparable between
groups, except for renal disease, which has emerged as a
critical feature in the outcome of SARS-CoV-2-infected
MM patients. Interestingly, the presence of lymphopenia
and higher levels of D-dimers and ferritin, laboratory
findings associated with higher mortality rates in several
global COVID-19 patient series2,4,24,25, were more com-
mon in MM vs noncancer patients. Nevertheless, the
mortality rate observed for MM patients is similar to that
reported in patients with other cancers (28.6%) and
hematologic diseases (33%), as well as immunocompro-
mised patients (27.8%)5,7,26,27.
Table 4 Prognostic factors of inpatient mortality in multiple myeloma (MM) patients hospitalized with COVID-19.
Prognostic factorsa N Inpatient
mortality, no. (%)






P value Odds ratio
(95% CI)
P value
All patients 167 56 (34)
Age > 65 years 112 47 (42) 3.7 (1.6–8.3) 0.002 3. (1.4–8.4) 0.006 NA NA
Males 95 39 (41) 2.3 (1.1–4.4) 0.018 3.8 (1.7–8.4) 0.001 NA NA
MM comorbidities and status at hospital admission for COVID-19
Renal disease 32 19 (59) 3.9 (1.7–8.7) <0.001 4.6 (1.9–11.3) <0.001 NA NA
Hypertension 67 28 (42) 1.8 (0.96–3.5) 0.065 1.7 (0.8–3.5) 0.18 NA NA
Active disease or progression 43 21 (49) 2.4 (1.2–4.9) 0.015 2.7 (1.2–6.0) 0.017 NA NA
Reference model: 0.7 0.79 (0.72–0.86)
MM features at diagnosis and treatment
Monoclonal component,
immunoglobulin G
83 22 (27) 0.5 (0.3–1.0) 0.05 0.6 (0.3–1.3) 0.18 0.6 0.80 (0.73–0.87)
Renal disease at diagnosis 45 23 (51) 2.8 (1.4–5.7) 0.004 1.3 (0.4–3.7) 0.6 0.8 0.79 (0.72–0.86)
Diagnosis in 2020 (time since
diagnosis ≤ 3 months)
25 12 (48) 2.0 (0.9–4.9) 0.10 2.7 (0.7–5.8) 0.19 0.5 0.79 (0.72–0.86)
Prior stem cell transplantation 51 9 (17) 0.3 (0.1–0.7) 0.004 0.6 (0.2–1.7) 0.4 0.4 0.79 (0.71–0.86)
CI confidence interval, COVID-19 coronavirus disease 2019, GoF goodness-of-fit, NA not applicable.
aPredefined set of well-established prognostic factors assessed before admission; all variables were dichotomized according to standard categories.
bCrude odds ratio and 95% confidence interval.
cEach logistic model included age, sex, myeloma status, comorbidities (hypertension, renal disease) at diagnosis of COVID-19 (reference model), and one variable from
the “Multiple myeloma at diagnosis and treatment” set. Calibration and discrimination of the models were assessed with the Hosmer–Lemeshow goodness-of-fit test
(GoF P value) and the c-statistic.
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The higher inpatient mortality rate in MM vs noncancer
patients can be explained through patient-related factors
and MM features, besides the biology of the disease itself.
Regarding patient-related factors, age >65 years and male
sex emerged as two of the most important risk factors
predicting inpatient mortality. Notably, and in contrast to
noncancer COVID-19 populations, in which 75 years has
been reported as the cutoff predicting peak risk of death,
the mortality rate in MM did not differ above 65 years of
age, suggesting that there are other factors intrinsic to
MM that influence the outcome. Regarding MM features,
renal insufficiency is a major hallmark of MM (one of the
four myeloma-defining events); in the present series, its
presence at hospital admission for COVID-19 emerged as
the most important factor for survival (OR= 3.8). Renal
impairment at diagnosis was also an adverse factor, but
this significance was lost in the adjusted multivariate
analysis. However, the strength of association with inpa-
tient mortality of renal insufficiency at admission
increased, and the independent prognostic value was
retained in the multivariate analysis. Indeed, kidney dis-
ease as a prognostic factor predicting increased inpatient
mortality rate in a general patient population has been
previously described in a single-center study in China28.
By contrast, hypertension as a comorbidity was not a
significant factor in the adjusted model. Other MM fea-
tures such as high-risk cytogenetics and immunoparesis
did not influence the outcome; the latter is of interest
since humoral immunodeficiency, which is common in
MM, would be considered a potential factor for elevated
risk. Additionally, we observed that IgG isotype and stage
I disease were associated with lower mortality.
Regarding MM status at hospital admission for COVID-
19, as would be expected, the presence of uncontrolled
disease had a detrimental effect on survival (OR= 2.6) and
was one of the independent factors predicting outcome.
This would help explain the significantly higher mortality
rate observed in patients diagnosed at the time of pandemic
(January–April 2020), since in most their disease was not
adequately controlled; it is well known that newly diagnosed
patients have an elevated risk of mortality due to infectious
complications in the first 3 months of treatment. The
benefit of disease control (complete/partial response) in the
context of COVID-19 would likewise explain the favorable
outcome observed in patients who had previously received
ASCT since most of them were in response.
The non-participation of MM patients with unconfirmed
COVID-19 or who were not hospitalized is a limitation in
terms of the broader applicability of the study results.
Further studies could be conducted to implement our
analysis protocol in a less restricted population of patients.
Another limitation is that our study is not able to identify
optimal management and treatment of newly diagnosed
MM patients with COVID-19.
In conclusion, MM patients hospitalized with SARS-
CoV-2 infection have a higher inpatient mortality rate
than noncancer patients. This had been suspected since
the beginning of the COVID-19 pandemic, and conse-
quently national and international societies have pub-
lished or made general recommendations about optimal
management of MM patients. Our study assessed the
impact of prior MM treatments based on immunomo-
dulatory drugs, proteasome inhibitors, or monoclonal
antibodies, and none of these influenced in the inpatient
mortality rate. Although we cannot answer the question
of whether to treat or not—and how—during the pan-
demic, we can stress the need for appropriate disease
control in all patients, to minimize hospital visits, parti-
cularly in the most vulnerable MM populations such as
male patients, those aged >65 years (who are already at
high risk, even at this relatively young age), and those with
renal impairment, which is the most critical factor.
Accordingly, MM patients requiring treatment due to
active disease should be tested for COVID-19 by PCR and,
if negative, we should proceed to optimize treatment in
the most protective environment possible. In patients
with the non-active disease, MM treatment could be
postponed for 1–2 months; however, if patients are
receiving maintenance therapy, treatment should con-
tinue. Further research is required to identify the most
effective treatments for COVID-19, as well as vaccination
strategies that should be employed as early as possible in
the most vulnerable patients. Future studies should vali-
date criteria for stratifying MM patients who are at greater
risk in a healthcare crisis such as the COVID-19 pan-
demic and who could benefit from reducing their risk-
exposure through a more stringent preventive strategy.
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